An interventional study of CO2gap-guided resuscitation strategy in Sepsis - to Reduce Mortality in the Intensive Care Unit and Septic Shock, sponsored by University Hospital, Clermont-Ferrand. Recruiting at 29 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by University Hospital, Clermont-Ferrand · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 184 studies in Shock, Septic with a site in France — 45 open to participants now, 50 under way, 7 of them phase 3. Shock, Septic · France.
Among the 184 studies in Shock, Septic with a site in France, this one is the 10th largest by planned enrollment of the 105 interventional ones that give a count, is one of 17 that started in 2026, is one of 52 with no phase, reaches primary completion later than 34 of the 49 other live ones, and was the 168th registered.
1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.
Browse Shock, Septic studies →45 of the 184 studies in Shock, Septic with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Centre National de la Recherche Scientifique, France · Sites in France
Ages 18–49 · Women only · Healthy volunteers
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
184 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 19 · Phase 3 32 · Phase 4 9
First in 1997; this study’s year is marked. 17 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 750 is above the median of 78 across 639 interventional studies indexed under Shock, Septic.
Median enrollment 120 across the 105 interventional studies, 100 across the 79 observational. Of the 108 that completed or were terminated, 6 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 184 have an industry lead sponsor. The 10 most frequent:
University Hospital, Clermont-Ferrand is the lead sponsor of 859 studies on the registry; 177 are open to participants now.
University Hospital, Clermont-Ferrand has 2 studies filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
13 of the studies in Shock, Septic with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04748796Phase 3Centre Hospitalier Universitaire, AmiensComparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility | 2027-06 |
| NCT07085624Centre Hospitalier Universitaire de Saint EtienneEarly Optimization of Ceftazidime Regimen in Critical Care | 2026-11 |
| NCT04067674Hospices Civils de LyonSeptic Shock-induced Immunosuppression | 2026-11-21 |
| NCT07354568Centre Hospitalier Universitaire, AmiensPrognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock | 2027-01-01 |
| NCT07199998Centre National de la Recherche Scientifique, FranceImpact of Internal Menstrual Protections on Immunity and Vaginal Microbiota | 2027-03 |
Add all 13 to your calendar (.ics) → With an account.
Among the 184 studies in Shock, Septic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sepsis is a dysregulated host response to infection that leads to life-threatening organ dysfunction and represents a major healthcare problem. Septic shock is the most severe form, characterized by increased capillary permeability and vasodilation, resulting in hypotension and tissue hypoxia. Early identification and treatment of tissue hypoperfusion are pivotal components of initial resuscitation to limit progression to multiple organ dysfunction and death. The 2021 Surviving Sepsis Guidelines recommend guiding initial resuscitation by targeting decreases in serum lactate levels in patients with elevated lactate. However, although elevated lactate levels may reflect tissue hypoxia, serum lactate is not a direct marker of tissue perfusion. Hyperlactatemia may be attributable to mechanisms other than tissue hypoperfusion, such as accelerated aerobic glycolysis driven by excessive β-adrenergic stimulation or impaired clearance (e.g., in liver failure).
The venous-to-arterial carbon dioxide partial pressure difference (CO₂ gap), which is inversely related to cardiac output, has been shown to reflect the adequacy of venous blood flow to remove CO₂ from tissues. The CO₂ gap is closely linked to microcirculatory blood flow during the early resuscitation phase of septic shock and may effectively identify persistent tissue hypoperfusion in shock states. A persistently high CO₂ gap during early resuscitation has been associated with significantly higher 28-day mortality and increased Sequential Organ Failure Assessment (SOFA) scores. Moreover, the CO₂ gap has been shown to respond to changes in cardiac output during inotrope infusion in patients with low blood flow, suggesting that its assessment could be useful for therapeutic adjustments. Therefore, there are compelling arguments to evaluate the usefulness of the CO₂ gap in guiding early resuscitation in patients with septic shock.
The investigators postulated that CO₂ gap-guided early resuscitation may be more effective in improving outcomes than lactate-guided resuscitation.
Main objective: The aim of the CARBON trial is to compare a veno-arterial CO2 difference-guided resuscitation strategy (CO2gap-guided strategy) with a lactate level-guided resuscitation on mortality in adults intensive care unit (ICU) patients fulfilling the SEPSIS-3 criteria consensus definition.
HYPOTHESIS: The investigators hypothesized that a CO2gap-guided resuscitation strategy during early septic shock would reduce mortality compared with a lactate level-guided resuscitation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Primary diagnosis of septic shock according to the Sepsis-3 criteria and defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CO2gap-guided resuscitation strategy aimed at maintaining central venous-to-arterial CO2 partial pressure difference (CO2gap) lower than 6 mmHg, using a sequential approach through a dedicated hemodynamic algorithm. Arterial and central venous blood samples will be drawn simultaneously and reassessed at 2 to 4-hour intervals
Procedure: CO2gap-guided resuscitation strategy
Lactate level-guided resuscitation strategy aimed at normalizing or decreasing lactate levels by 20% at 2 to 4-hour intervals, as per the surviving sepsis campaign guidelines.
For patients assigned to the interventional arm, adherence to the algorithm will complement clinical practices in the following areas: * Blood sampling for venous blood gas analysis. Blood samples will be taken from an existing central venous catheter; central venous access is common clinical practice in critically ill patients. * The use of dobutamine and blood transfusions in patients showing signs of oxygen deficiency (both will be carried out in accordance with the intended use and conditions of current practice).
The primary end point is all-cause mortality at 28 days after randomization
Time frame: Every day until Day 28
Key secondary endpoints
Duration of septic shock (i.e., vasopressor use) up to Day 28
Time frame: Every day until Day 28
Key secondary endpoints
All-cause mortality at Day 90
Time frame: Every day until Day 90
Secondary Efficacy Endpoints
Vasopressor-free and inotrope-free days up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
Renal replacement therapy-free days (excluding patients on renal replacement therapy at time of randomization) up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
Mechanical ventilation-free days up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
Duration of renal replacement therapy (excluding patients on renal replacement therapy at time of randomization) up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
Duration of mechanical ventilation up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
Incidence of new organ dysfunction (based on the SOFA score) up to Day 7
Time frame: Every day until Day 7
Secondary Efficacy Endpoints
ICU-free days up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
ICU length of stay up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
Hospital length of stay up to Day 28
Time frame: Every day until Day 28
Secondary Efficacy Endpoints
EuroQol 5 Dimensions, 5 Levels (EQ-5D-5L) :a measure of health-related quality of life at Day 90: The EQ-5D-5L score is analyzed using the utility value (global index score). In France, the score ranges from about -0.53 (health states considered worse than death) to 1.00 (full health). 0.00 corresponds to a health state equivalent to death.
Time frame: At Day 90 after randomization
Secondary Safety Endpoints
Incidence of adverse events with specific emphasis on the incidence of ischemic (e.g., myocardial, stroke, intestinal, limb ischemia) and arrhythmia (excluding sinus tachycardia or sinus arrhythmia) events reported as having a reasonable possibility of a causal relationship with the study procedures
Time frame: Every day until Day 28
Plan to share: No
Started Mar 2026 (actual). Primary completion is estimated for Nov 2027, 20 months after the start.
Of 165 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 20 months is below that.
Counting every sponsor, half of 173 studies reached it within 25 months; a quarter within 12 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Clermont-Ferrand →